Repro Med Systems Inc (REPR)

[blue_skies]

whyte - here is what I am expecting. 20% plus YOY top line growth. Some sales from last quarter were pushed into this quarter. Hoping to see a penny/share bottom line minimum. I expect to see some increase in R&D expenses and patent related expenses. There will also be some expenses related to the never ending lawsuit with a competitor. Looking for improving gross margins??

Looking to hear what if anything is said about early on relationships with drug companies. Below is a quote from March presentation:
"Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets"